Pulse Biosciences
Pulse Biosciences is a clinical-stage bioelectric medicine company developing proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation, benign thyroid nodules, and other soft tissue conditions, serving electrophysiologists, cardiac surgeons, and interventional endocrinologists.
- Company typePublic
- Founded2014
- HeadquartersHayward, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pulse Biosciences does
Pulse Biosciences is a clinical-stage bioelectric medicine company developing a proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology platform that delivers nanosecond-duration electrical pulses to create nanopores in cellular membranes, triggering regulated cell death while sparing adjacent noncellular tissue structures such as vessels, nerves, and connective tissue. The company's product portfolio is built around a shared nsPFA console generator and includes the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation (used in benign thyroid nodules), the investigational nsPFA 360 Catheter Endocardial Ablation System for catheter-based atrial fibrillation ablation, and the investigational nsPFA Cardiac Surgery Ablation System (cardiac clamp) for open concomitant surgical AF procedures. The lead cardiac program is supported by the NANOPULSE-AF IDE pivotal study planning enrollment of approximately 215 patients across up to 30 sites in the U.S. and Europe, alongside the parallel NANOCLAMP AF study, with clinical data showing 96% procedural success at 12 months and 1.7% serious adverse event rates in the European feasibility cohort.
The business operates a direct enterprise field sales model targeting hospitals, electrophysiology labs, and cardiac surgery centers, with demand generation concentrated at major medical conferences (Heart Rhythm Society, AF Symposium, NASIT) and physician key opinion leader networks. Revenue is generated through hardware sales of consoles, catheters, and electrodes, supplemented by clinical procedure revenue at treatment centers; full-year 2025 revenue was $350K and Q1 2026 revenue was $401K, reflecting the early commercial stage of the only FDA-cleared product. The company has integrated its catheter with Abbott's EnSite X and Johnson & Johnson's CARTO 3 electroanatomical mapping systems to fit into standard electrophysiology lab workflows. Capital structure is concentrated: majority shareholder Robert W. Duggan owns approximately 69% of outstanding shares following $115M of private placements in 2021 and 2023, a $60M rights offering in 2024, and a $13.3M insider ATM purchase in May 2026, with cash of $80.7M as of Q4 2025 against a $72.8M full-year GAAP net loss.
Pulse Biosciences firmographics
Firmographics- Name
- Pulse Biosciences
- Legal name
- Pulse Biosciences, Inc.
- Website
- https://pulsebiosciences.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Pulse Biosciences is a clinical-stage bioelectric medicine company developing proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation, benign thyroid nodules, and other soft tissue conditions, serving electrophysiologists, cardiac surgeons, and interventional endocrinologists.
- Ownership category
- akta.pro rank
Pulse Biosciences industry classification
Industry- Product category
- Cardiac Ablation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industry
- Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)
Keywords
Where Pulse Biosciences is headquartered
LocationHeadquarters
- HQ city
- Hayward
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pulse Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- nPulse/Vybrance System Sales: Revenue generated from sale of nPulse ablation systems including consoles, catheters, and electrodes to healthcare providers and hospitals for clinical procedures and trials.
- Clinical Procedure Revenue: Revenue from medical procedures using nPulse technology at treatment centers. Q1 2026 reported $401,000 in revenue; Q4 2025 reported $264,000 primarily from Vybrance systems and electrodes.
- At-the-Market Equity Offerings: Company raises capital through at-the-market equity offering programs. In May 2026, co-chairmen purchased $13.3 million of company stock through the ATM program managed by TD Securities.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Pulse Biosciences product offering
Product offeringCore offering
Pulse Biosciences develops and commercializes medical devices based on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The company sells the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation and is developing investigational devices—the nsPFA 360 Catheter Endocardial Ablation System and the nsPFA Cardiac Surgical Clamp—for treating atrial fibrillation through catheter-based and open surgical approaches. All systems rely on a shared nsPFA Console generator that delivers nanosecond electrical pulses to induce regulated cell death while sparing noncellular tissue.
Product overview
Pulse Biosciences offers a platform-based product portfolio built around its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The nPulse Vybrance Percutaneous Electrode System is FDA-cleared for soft tissue ablation in percutaneous and intraoperative procedures. The nsPFA 360 Catheter Endocardial Ablation System and nsPFA Cardiac Surgery Ablation System (nPulse Cardiac Clamp) are investigational devices for treating atrial fibrillation through catheter-based and surgical approaches respectively. All cardiac products share the nsPFA Console as the common generator platform, which delivers the underlying nanosecond pulsed field energy that enables cell-targeting ablation while sparing adjacent noncellular tissue structures.
Differentiator
Problem solved
Functional benefit
Brands
- CellFX: Brand name for the company's nsPFA technology platform used for cardiac applications.
- nPulse Vybrance
- nsPFA 360 Catheter
- nsPFA Cardiac Clamp
Products and services
- nPulse Vybrance Percutaneous Electrode System FDA-cleared percutaneous electrode system utilizing Nanosecond Pulsed Field Ablation (nsPFA) energy for ablation of soft tissue in percutaneous and intraoperative surgical procedures. It induces regulated cell death while sparing adjacent acellular tissue including vessels, nerves, and connective tissue, used for benign thyroid nodule ablation.
- nsPFA 360 Catheter Endocardial Ablation System Investigational cardiac catheter system for endocardial ablation during electrophysiology procedures, comprising the nsPFA Console and nsPFA 360 Catheter with integrated sensing electrodes, designed to create circumferential ablation for pulmonary vein isolation while sparing acellular tissue in atrial fibrillation treatment.
- nsPFA Cardiac Surgery Ablation System (nPulse Cardiac Clamp) Investigational cardiac surgical clamp system using nsPFA technology for ablation during open concomitant surgical atrial fibrillation procedures. Available in 53mm or 65mm jaw lengths, designed to create continuous linear transmural ablations while minimizing damage to surrounding acellular tissue.
- nsPFA Console (Generator Platform) Power generator platform that delivers Nanosecond Pulsed Field Ablation energy for the nPulse product family. Operated via integrated touch screen and foot pedal, the console generates nanosecond PFA energy designed to induce regulated cell death of treated cardiac tissue while shielding interconnected lab equipment.
Quantifiable outcome
- 96% procedural success at 12 months follow-up for atrial fibrillation treatment
- +6 more outcomes
Companies that use Pulse Biosciences
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Pulse Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature6 records
Pulse Biosciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- The University of Texas MD Anderson Cancer CentercoreResearch collaboration to evaluate nPulse technology for treating thyroid cancers, with planned clinical study for papillary thyroid microcarcinoma treatment beginning early 2026. Preclinical studies on anaplastic thyroid carcinoma are ongoing. This collaboration extends the nsPFA platform into oncology applications.
- AbbottcorenPulse Cardiac Catheter System is integrated with Abbott's EnSite X 3D electroanatomical mapping system for pulmonary vein isolation procedures. Integration enables procedural workflow combining nPulse ablation with Abbott's mapping technology.
- Johnson & Johnson (Biosense Webster)corensPFA 360 Catheter integrated with CARTO 3 Mapping System from Johnson & Johnson for live case demonstrations at HRS 2025. Integration enables combined ablation and mapping workflow for atrial fibrillation procedures.
Scale indicators11 records
Recent moves6 records
Expansion highlights7 records
Pulse Biosciences competitors and assessment
Company assessmentDirect peers
- Boston Scientific: Boston Scientific's FARAPULSE pulsed field ablation system is the leading commercial PFA catheter for atrial fibrillation, directly competing with Pulse Biosciences' nPulse 360 Catheter in the same EP lab workflow and AF indication.
- Johnson & Johnson (Biosense Webster): Biosense Webster's CARTO 3 mapping and ThermoCool/Smart-Touch PFA catheters compete directly in AF ablation, and Pulse Biosciences' catheter is already integrated with CARTO 3, making J&J both a partner and a direct competitor.
- Abbott: Abbott's EnSite X mapping system and TactiFlex PFA catheter compete in EP ablation; Pulse Biosciences integrates with EnSite X, positioning Abbott as both a workflow partner and competitive incumbent.
- Medtronic: Medtronic's PulseSelect and Affera-derived PFA systems target the same AF ablation market as Pulse Biosciences' nPulse 360, with a deep EP installed base and global commercial reach.
- AtriCure: AtriCure is the dominant player in surgical AF ablation (the Isolator Synergy clamp and cryo devices) and is the closest direct competitor to Pulse Biosciences' nsPFA Cardiac Clamp in the open concomitant surgical AF setting.
- AngioDynamics: AngioDynamics markets the NanoKnife irreversible electroporation system, the closest direct mechanistic peer to nsPFA, used for soft tissue ablation including prostate and pancreatic lesions, with overlap on the Vybrance non-cardiac indication.
Emerging players
- Galvanize Therapeutics: Galvanize Therapeutics is a private pulsed electric field company developing EP and oncology ablation platforms, intersecting with both Pulse's cardiac catheter and soft tissue/oncology roadmaps as an emerging PFA competitor.
- Adagio Medical: Adagio Medical develops a cryo-PFA hybrid catheter for AF ablation, positioning it as a partial-overlap emerging competitor to Pulse's nPulse 360 in the paroxysmal and persistent AF EP market.
- Penumbra: Penumbra has expanded from thrombectomy into the electrophysiology and PFA space through Lightning Flash and related catheter platforms, creating indirect competition with Pulse's cardiac ablation program.
Regional players
- MicroPort Scientific: MicroPort's EP division (formerly Cardiac Rhythmic Technologies and acquired assets) markets cardiac ablation products in Asia and Europe, representing a regional PFA/AF ablation competitor to Pulse's eventual global rollout.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Pulse Biosciences social profiles
Digital presencePulse Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pulse Biosciences leadership team
Management profileNumber of profiles
Profiles13 records
Pulse Biosciences funding detail
Funding detailFunding overview
Funding rounds9 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pulse Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pulse Biosciences
What does Pulse Biosciences do?
Pulse Biosciences develops and commercializes medical devices based on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The company sells the FDA-cleared nPulse Vybrance Percutaneous Electrode System for soft tissue ablation and is developing investigational devices—the nsPFA 360 Catheter Endocardial Ablation System and the nsPFA Cardiac Surgical Clamp—for treating atrial fibrillation through catheter-based and open surgical approaches. All systems rely on a shared nsPFA Console generator that delivers nanosecond electrical pulses to induce regulated cell death while sparing noncellular tissue.
Is Pulse Biosciences a public or private company?
Pulse Biosciences is a public company. It is classified as public and is currently operating.
When was Pulse Biosciences founded?
Pulse Biosciences was founded in 2014. It employs 101 to 250 people.
Where is Pulse Biosciences based?
Pulse Biosciences is headquartered in Hayward, United States, in the North America region.
How does Pulse Biosciences make money?
Three revenue lines are on record. nPulse/Vybrance System Sales are the primary driver. The others are clinical Procedure Revenue and at-the-Market Equity Offerings.
Who are Pulse Biosciences's main competitors?
Direct peers on record are Boston Scientific, Johnson & Johnson (Biosense Webster), Abbott, Medtronic, AtriCure and AngioDynamics. Emerging players are Galvanize Therapeutics, Adagio Medical and Penumbra. MicroPort Scientific is listed as a regional player.
Does Pulse Biosciences have an API?
No public API is recorded for Pulse Biosciences.
What industry is Pulse Biosciences in?
Pulse Biosciences's product category is Cardiac Ablation Medical Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser). Its NAICS code is 334510 and its SIC code is 3845.